Explore the vast range of titles available.

Bibliometrics has become an essential tool for assessing and analyzing the output of scientists, cooperation between universities, the effect of state-owned science funding on national research and development performance and educational efficiency, among other applications. Therefore, professionals and scientists need a range of theoretical and practical tools to measure experimental data. This review aims to provide an up-to-date review of the various tools available for conducting bibliometric and scientometric analyses, including the sources of data acquisition, performance analysis and visualization tools. The included tools were divided into three categories: general bibliometric and performance analysis, science mapping analysis, and libraries; a description of all of them is provided. A comparative analysis of the database sources support, pre-processing capabilities, analysis and visualization options were also provided in order to facilitate its understanding. Although there are numerous bibliometric databases to obtain data for bibliometric and scientometric analysis, they have been developed for a different purpose. The number of exportable records is between 500 and 50,000 and the coverage of the different science fields is unequal in each database. Concerning the analyzed tools, Bibliometrix contains the more extensive set of techniques and suitable for practitioners through Biblioshiny. VOSviewer has a fantastic visualization and is capable of loading and exporting information from many sources. SciMAT is the tool with a powerful pre-processing and export capability. In views of the variability of features, the users need to decide the desired analysis output and chose the option that better fits into their aims.

Covid-19 represents the greatest challenge facing mankind today. In December 2019, several cases of pneumonia of unknown etiology were reported from China. This coronavirus infection subsequently identified as Covid-19 aroused worldwide concern. As a result, the scientific community has focused attention on Covid-19, as revealed by recent research reported in literature based on a holistic approach. In this regard, this study conducts a bibliometric analysis of coronavirus research in the literature with an emphasis on Covid-19 disease, using as a reference the publications in the Web of Science Core Collection from 1970 to 2020. This research analyzes 12,571 publications from 1970 to (April 18) 2020 by applying advanced bibliometric techniques in SciMAT bibliometric analysis software. The current research therefore provides a complete conceptual analysis of the main coronavirus types and strains in the literature by quantifying the main bibliometric performance indicators, identifying the main authors, organizations, countries, sources, and research areas, and evaluating the development of this field. Furthermore, a science map is constructed to understand the corresponding intellectual structure and main research lines (themes). SciMAT thereby offers a complete approach to the field and evaluates the main performance indicators related to coronavirus, with a focus on Covid-19. Finally, this research serves as a framework to strengthen existing research lines and develop new ones, establishing synergistic relationships that were not visible without the maps generated herein.

In patients with lung cancer, neoadjuvant treatment with nivolumab and chemotherapy resulted in a significantly higher percentage of patients with a pathological complete response than chemotherapy alone.

Non-small-cell lung cancer (NSCLC) is terminal in most patients with locally advanced stage disease. We aimed to assess the antitumour activity and safety of neoadjuvant chemoimmunotherapy for resectable stage IIIA NSCLC. This was an open-label, multicentre, single-arm phase 2 trial done at 18 hospitals in Spain. Eligible patients were aged 18 years or older with histologically or cytologically documented treatment-naive American Joint Committee on Cancer-defined stage IIIA NSCLC that was deemed locally to be surgically resectable by a multidisciplinary clinical team, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients received neoadjuvant treatment with intravenous paclitaxel (200 mg/m2) and carboplatin (area under curve 6; 6 mg/mL per min) plus nivolumab (360 mg) on day 1 of each 21-day cycle, for three cycles before surgical resection, followed by adjuvant intravenous nivolumab monotherapy for 1 year (240 mg every 2 weeks for 4 months, followed by 480 mg every 4 weeks for 8 months). The primary endpoint was progression-free survival at 24 months, assessed in the modified intention-to-treat population, which included all patients who received neoadjuvant treatment, and in the per-protocol population, which included all patients who had tumour resection and received at least one cycle of adjuvant treatment. Safety was assessed in the modified intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT03081689, and is ongoing but no longer recruiting patients. Between April 26, 2017, and Aug 25, 2018, we screened 51 patients for eligibility, of whom 46 patients were enrolled and received neoadjuvant treatment. At the time of data cutoff (Jan 31, 2020), the median duration of follow-up was 24·0 months (IQR 21·4–28·1) and 35 of 41 patients who had tumour resection were progression free. At 24 months, progression-free survival was 77·1% (95% CI 59·9–87·7). 43 (93%) of 46 patients had treatment-related adverse events during neoadjuvant treatment, and 14 (30%) had treatment-related adverse events of grade 3 or worse; however, none of the adverse events were associated with surgery delays or deaths. The most common grade 3 or worse treatment-related adverse events were increased lipase (three [7%]) and febrile neutropenia (three [7%]). Our results support the addition of neoadjuvant nivolumab to platinum-based chemotherapy in patients with resectable stage IIIA NSCLC. Neoadjuvant chemoimmunotherapy could change the perception of locally advanced lung cancer as a potentially lethal disease to one that is curable. Bristol-Myers Squibb, Instituto de Salud Carlos III, European Union's Horizon 2020 research and innovation programme.

Targeted inhibition of the PD-L1–PD-1 pathway might be further amplified through combination of PD-1 or PD-L1 inhibitors with novel anti-TIGIT inhibitory immune checkpoint agents, such as tiragolumab. In the CITYSCAPE trial, we aimed to assess the preliminary efficacy and safety of tiragolumab plus atezolizumab (anti-PD-L1) therapy as first-line treatment for non-small-cell lung cancer (NSCLC). CITYSCAPE is a phase 2, randomised, double-blind, placebo-controlled trial. Patients with chemotherapy-naive, PD-L1-positive (defined as a tumour proportion score of ≥1% by 22C3 immunohistochemistry pharmDx assay; Dako, Agilent Technologies, Santa Clara, CA, USA) recurrent or metastatic NSCLC with measurable disease, Eastern Cooperative Oncology Group performance status of 0 or 1, and no EGFR or ALK alterations were enrolled from 41 clinics in Europe, Asia, and the USA. Patients were randomly assigned (1:1), via an interactive voice or web-based response system, to receive tiragolumab (600 mg) plus atezolizumab (1200 mg) or placebo plus atezolizumab intravenously once every 3 weeks. Investigators and patients were masked to treatment assignment. The co-primary endpoints were investigator-assessed objective response rate and progression-free survival as per Response Evaluation Criteria in Solid Tumors version 1.1 in the intention-to-treat population, analysed after approximately 80 progression-free survival events had been observed in the primary population. Safety was assessed in all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT03563716, and is ongoing. Patients were enrolled between Aug 10, 2018, and March 20, 2019. At data cutoff for the primary analysis (June 30, 2019), 135 of 275 patients assessed for eligibility were randomly assigned to receive tiragolumab plus atezolizumab (67 [50%]) or placebo plus atezolizumab (68 [50%]). In this primary analysis, after a median follow-up of 5·9 months (4·6–7·6, in the intention-to-treat population, 21 patients (31·3% [95% CI 19·5–43·2]) in the tiragolumab plus atezolizumab group versus 11 patients (16·2% [6·7–25·7]) in the placebo plus atezolizumab group had an objective response (p=0·031). Median progression-free survival was 5·4 months (95% CI 4·2–not estimable) in the tiragolumab plus atezolizumab group versus 3·6 months (2·7–4·4) in the placebo plus atezolizumab group (stratified hazard ratio 0·57 [95% CI 0·37–0·90], p=0·015). 14 (21%) patients receiving tiragolumab plus atezolizumab and 12 (18%) patients receiving placebo plus atezolizumab had serious treatment-related adverse events. The most frequently reported grade 3 or worse treatment-related adverse event was lipase increase (in six [9%] patients in the tiragolumab plus atezolizumab group vs two [3%] in the placebo plus atezolizumab group). Two treatment-related deaths (of pyrexia and infection) occurred in the tiragolumab plus atezolizumab group. Tiragolumab plus atezolizumab showed a clinically meaningful improvement in objective response rate and progression-free survival compared with placebo plus atezolizumab in patients with chemotherapy-naive, PD-L1-positive, recurrent or metastatic NSCLC. Tiragolumab plus atezolizumab was well tolerated, with a safety profile generally similar to that of atezolizumab alone. These findings demonstrate that tiragolumab plus atezolizumab is a promising immunotherapy combination for the treatment of previously untreated, locally advanced unresectable or metastatic NSCLC. F Hoffmann-La Roche and Genentech.

Communication research field has an extraordinary growth pattern, indeed bigger than other research fields. In order to extract knowledge from such amount, intelligent techniques are need. In such a way, using bibliometric techniques, the evolution of the conceptual, social and intellectual aspects of this research field could be analysed, and hence, understood. Although the communication research field has been widely analysed using bibliometric techniques and science mapping tools, a conceptual analysis of the whole communication research field is still needed. Therefore, this article introduces the first science mapping analysis in the communication research field based on the Web of Science Subject Category \"Communication\", showing its conceptual structure and scientific evolution. SciMAT, a bibliometric science mapping software tool based on co-word analysis and h-index, is applied using a sample of 33.627 research documents from 1980 to 2013 published in 74 main communication journals indexed in the Journal Citation Reports of the Web of Science. The results show that research conducted in the communication research is concentrated on the following sixteen disconnected thematic areas: \"children\", \"psychological aspects\", \"news\", \"audience\", \"surveys\", \"advertising\", \"health\", \"relationship\", \"gender\", \"discourse\", \"telephone communication\", \"public relation\", \"telecommunications\", \"public opinion\", \"activism\" and \"Internet\". These areas have progressively disconnected among them, which drives to a Communication field relatively fragmented.

Ocean acidification and warming are challenging marine organisms and ecosystems around the world. The synergetic effects of these two climate change stressors on jellyfish remain still understudied. Here, we examine the independent and combined effects of these two environmental variables on polyp population dynamics of the Mediterranean jellyfish Cotylorhiza tuberculata . An experiment was conducted to examine asexual reproduction by budding and strobilation considering current and ca. 2100 winter (Trial 1, 36 days) and summer (Trial 2, 36 days) conditions under the RCP8.5 (IPCC 2013). In Trial 1, a temperature of 18°C and two pH levels (current: 7.9 and, reduced: 7.7) were tested. Trial 2 considered two temperature levels 24°C and 30°C, under current and reduced acidification conditions (8.0 and 7.7, respectively). Ephyrae size and statolith formation of released ephyrae from polyps exposed to summer temperatures under both acidification treatment was also analyzed. Zooxanthellae density inside the polyps throughout the experiment was measured. C . tuberculata polyps could cope with the conditions mimicked in all experimental treatments and no significant effect of pH, temperature, or the combination of both variables on the abundance of polyps was observed. At 18°C, strobilation was reduced under high P CO2 conditions. Under summer treatments (24°C and 30°C), percentage strobilation was very low and several released ephyrae suffered malformations and reduced size, as a consequence of reduced pH and elevated temperatures, separately. The number of statoliths was not affected by pH or temperature, however, bigger statoliths were formed at elevated temperatures (30°C). Finally, zooxanthellae density was not affected by experimental conditions, even if, the duration of the experiment significantly affected symbiont concentration. Our results show that even though polyps of C . tuberculata would thrive the future worst scenario predicted for the Mediterranean Sea, their capacity to undergo a proper strobilation and to produce healthy ephyrae will be more vulnerable to climate induced environmental conditions, thereby affecting medusae recruitment and, therefore, population dynamics of the species.

Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 interactions, reinvigorating anticancer immunity. We assessed its efficacy and safety versus docetaxel in previously treated patients with non-small-cell lung cancer. We did a randomised, open-label, phase 3 trial (OAK) in 194 academic or community oncology centres in 31 countries. We enrolled patients who had squamous or non-squamous non-small-cell lung cancer, were 18 years or older, had measurable disease per Response Evaluation Criteria in Solid Tumors, and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer. Patients with a history of autoimmune disease and those who had received previous treatments with docetaxel, CD137 agonists, anti-CTLA4, or therapies targeting the PD-L1 and PD-1 pathway were excluded. Patients were randomly assigned (1:1) to intravenously receive either atezolizumab 1200 mg or docetaxel 75 mg/m2 every 3 weeks by permuted block randomisation (block size of eight) via an interactive voice or web response system. Coprimary endpoints were overall survival in the intention-to-treat (ITT) and PD-L1-expression population TC1/2/3 or IC1/2/3 (≥1% PD-L1 on tumour cells or tumour-infiltrating immune cells). The primary efficacy analysis was done in the first 850 of 1225 enrolled patients. This study is registered with ClinicalTrials.gov, number NCT02008227. Between March 11, 2014, and April 29, 2015, 1225 patients were recruited. In the primary population, 425 patients were randomly assigned to receive atezolizumab and 425 patients were assigned to receive docetaxel. Overall survival was significantly longer with atezolizumab in the ITT and PD-L1-expression populations. In the ITT population, overall survival was improved with atezolizumab compared with docetaxel (median overall survival was 13·8 months [95% CI 11·8–15·7] vs 9·6 months [8·6–11·2]; hazard ratio [HR] 0·73 [95% CI 0·62–0·87], p=0·0003). Overall survival in the TC1/2/3 or IC1/2/3 population was improved with atezolizumab (n=241) compared with docetaxel (n=222; median overall survival was 15·7 months [95% CI 12·6–18·0] with atezolizumab vs 10·3 months [8·8–12·0] with docetaxel; HR 0·74 [95% CI 0·58–0·93]; p=0·0102). Patients in the PD-L1 low or undetectable subgroup (TC0 and IC0) also had improved survival with atezolizumab (median overall survival 12·6 months vs 8·9 months; HR 0·75 [95% CI 0·59–0·96]). Overall survival improvement was similar in patients with squamous (HR 0·73 [95% CI 0·54–0·98]; n=112 in the atezolizumab group and n=110 in the docetaxel group) or non-squamous (0·73 [0·60–0·89]; n=313 and n=315) histology. Fewer patients had treatment-related grade 3 or 4 adverse events with atezolizumab (90 [15%] of 609 patients) versus docetaxel (247 [43%] of 578 patients). One treatment-related death from a respiratory tract infection was reported in the docetaxel group. To our knowledge, OAK is the first randomised phase 3 study to report results of a PD-L1-targeted therapy, with atezolizumab treatment resulting in a clinically relevant improvement of overall survival versus docetaxel in previously treated non-small-cell lung cancer, regardless of PD-L1 expression or histology, with a favourable safety profile. F. Hoffmann-La Roche Ltd, Genentech, Inc.

Gender equity remains a challenge both globally and within academia, despite recent efforts to change it. Moreover, beyond the authors’ productivity, studies have reported that women often achieve lower scientific impact than their peers. To shed light on this complex relationship between the scientific impact and the themes addressed, this study conducts a comprehensive analysis of Library and Information Science field from 2007 to 2022 in four consecutive slides, identifying the principal themes covered in the field, analyzing the relative gender contribution rate, employing strategic diagrams, and assessing impact metrics, such as mean normalized citation score, 1% of most cited papers, and H-Classic. We employed science mapping analysis to explore a core of 45,650 documents from the Web of Science, with gender identification in 94.25% of cases. Our findings revealed a slight increase in the percentage of women authors within the field across the time, and a decline during the COVID-19 pandemic, demonstrating consistency in the themes addressed over the years. Women were overrepresented in the classic themes of LIS, human, and health-related fields, with these themes displaying lower performance rates. In contrast, men authors were overrepresented in STEM-related fields and innovation themes, associated with higher metric values. Our findings underlined the potential association between research themes and scientific performance, and provide societal and structural explanations for these observations. This study contributes valuable insights into the relationship between research themes and the scientific impact achieved by researchers in LIS, highlighting the importance of encouraging women’s participation in diverse knowledge domains and challenging prevailing stereotypes within academic and professional spheres.

Environmental knowledge is attracting interest in the area of sustainability due to the importance of both the environment and knowledge. As tourism is one of the biggest employers and sectors of economic development, environmental knowledge in hospitality represents a worldwide challenge. The present study aims to provide a clear understanding of the impacts and implications of environmental knowledge in the hospitality industry in a COVID society, taking into account its general areas of evolution through a systematic review methodology using a bibliographic database over time (26 years). We reviewed 944 documents collected from the Web of Science (WoS) Core Collection database and analysed them using the Science Mapping Analysis Software Tool (SciMAT). In a world in which the environment is more deteriorated, it is important to be aware of the advance in environmental knowledge to take care of it and eliminate environmental degradation. This study adds value to the orchestration of knowledge by focusing on predictors that impact environmental knowledge. The results identify the development status and leading trends in environmental knowledge research to fall in love with the future in a COVID society. Falling in love with the future is possible in the hospitality industry.